Treatment of Atrophic Nonunion by Preosteoblast Cells

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jean-Philippe Hauzeur, University Hospital of Liege
ClinicalTrials.gov Identifier:
NCT00916981
First received: June 3, 2009
Last updated: February 22, 2012
Last verified: February 2012

June 3, 2009
February 22, 2012
November 2008
June 2009   (final data collection date for primary outcome measure)
radiological progression of bone fusion [ Time Frame: 1, 2, 3, 4, 5, 6 months ] [ Designated as safety issue: No ]
monthly
radiological progression of bone fusion [ Time Frame: every months between 1-6 month ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00916981 on ClinicalTrials.gov Archive Site
reduction of pain using VAS [ Time Frame: each month ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Treatment of Atrophic Nonunion by Preosteoblast Cells
Treatment of Refractory Non-union Fractures by Pre-osteoblast Cells Grafting : a Pilot Study.

Treatment of nonunion, delayed union and malunion fractures of long bones remains problematic. The definition of nonunion is a failure of the fracture to heal in six months in a patient in whom progressive repair had not been observed radiographically between the third and sixth month after the fracture. First of all good surgical techniques are stable immobilization must be obtained and local sepsis excluded. Then stimulation of the callus is required. Numerous techniques have been developed ranging from invasive interventions (including internal fixation with the use of bone graft or bone graft substitutes) to non invasive procedures (ultrasound and pulsed electromagnetic fields).

Recently, autologous cell therapy was presented as an interesting approach. The concept of such therapies is based on the effect of stem cells presented in the bone marrow and able to be transformed in osteoblast cells. The percutaneous technique of autologous bone-marrow grafting is a minimally invasive alternative able to produce a good healing of the fracture. The efficacy is dependent of the concentration in progenitor cell reinjected. An optimization of this type of treatment could be achieved using a technique to increase the differentiation of the bone marrow cells in preosteoblasts before the injection in situ by an adequate culture. Therefore we would like to start a pilot open study on the feasibility and the efficacy of implantation of preosteoblasts into nonunion. Two different presentations exist: the atrophic and the hypertrophic pseudarthrosis in relationship with radiological features of bone proliferation at the tip of bone fragments. Some data support that atrophic and hypertrophic nonunion fractures could have different physiopathological factors. So, in a first time we only would evaluate the atrophic form and to determine in an open study the effect of the implantation of preosteoblasts into atrophic nonunion.

We will recruit 30 patients having a atrophic nonunion fracture of long bone present for minimum 6 months.50 ml of bone marrow harvest will be performed under local anaesthesia 3 weeks before the implantation. After three weeks of culture, preosteoblastic cells will be injected into the site of pseudarthrosis under radioscopic control, using percutaneously a 3 mm trephine.

An immobilization and non weight-bearing of the bone will be respected during the first month after the injection. If callus could be observed on radiographs, partial mobilization and weight-bearing will be allowed during the second month.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Pseudarthrosis
  • Fractures, Ununited
Procedure: percutaneous autologous preosteoblast cells implantation
percutaneously injection of preosteoblast into the nonunion under radioscopic control
Other Name: PREOB
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
June 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Fracture of a long bone having insufficient healing after minimum 6 months.
  • Be able and willing to participate in the study.

Exclusion Criteria:

  • Evidence of malignant disorder in the past five year.
  • Patient who is positive for an HIV, hepatitis B or C infection.
  • Insufficient reduction of the fracture with displaced fragments.
  • Evidence of local sepsis by biological parameters and/or positive isotopic scan using leucocytes labelled by Indium.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT00916981
ref:2006-73
No
Jean-Philippe Hauzeur, University Hospital of Liege
Jean-Philippe Hauzeur
Not Provided
Principal Investigator: Jean-Philippe Hauzeur, MD, PhD University of Liège, Belgium
University Hospital of Liege
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP